AbCellera Biologics (ABCL) Common Equity (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Common Equity came in at $938.1 million in Q1 2026, down 8.3% YoY from $1.0 billion in Q1 2025, and down 2.98% on a QoQ basis from $966.9 million in Q4 2025.
AbCellera Biologics (ABCL) Common Equity (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Common Equity data on file, last reported at $938.1 million in Q1 2026.
- Quarterly Common Equity fell 8.3% year-over-year to $938.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $938.1 million (down 8.3% YoY) and the FY2025 annual result came in at $966.9 million, down 8.44% from the prior year.
- Common Equity eased to $938.1 million in Q1 2026, from $966.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.3 billion in Q3 2022 to a low of $938.1 million in Q1 2026.
- A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 31.13% — and 2025, when it declined 10.58%.
- Tracing ABCL's Common Equity over 5 years: stood at $1.2 billion in 2022, then retreated by 6.56% to $1.2 billion in 2023, then slipped by 8.35% to $1.1 billion in 2024, then declined by 8.44% to $966.9 million in 2025, then declined by 2.98% to $938.1 million in 2026.
- The last three Common Equity figures came in at $938.1 million (Q1 2026), $966.9 million (Q4 2025), and $964.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 896.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 896.02 Mn |
| Mar 31, 2026 | 938.08 Mn |
| Dec 31, 2025 | 966.90 Mn |
| Sep 30, 2025 | 964.04 Mn |
| Jun 30, 2025 | 1.01 Bn |
| Mar 31, 2025 | 1.02 Bn |
| Dec 31, 2024 | 1.06 Bn |
| Sep 30, 2024 | 1.08 Bn |
| Jun 30, 2024 | 1.11 Bn |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | 1.15 Bn |
| Sep 30, 2023 | 1.18 Bn |
| Jun 30, 2023 | 1.19 Bn |
| Mar 31, 2023 | 1.21 Bn |
| Dec 31, 2022 | 1.23 Bn |
| Sep 30, 2022 | 1.25 Bn |
| Jun 30, 2022 | 1.21 Bn |
| Mar 31, 2022 | 1.21 Bn |
| Dec 31, 2021 | 1.03 Bn |
| Sep 30, 2021 | 953.40 Mn |